Wardzala, 2023 - Google Patents
Expanding the Toolbox: Engineering Mucin Glycoproteins to Investigate Viral Disease and Other PhenomenaWardzala, 2023
- Document ID
- 13881106405923310614
- Author
- Wardzala C
- Publication year
External Links
Snippet
Mucins are heavily-glycosylated proteins that comprise mucus, a hydrogel that blankets and protects the epithelium, and the glycocalyx, a saccharide barrier that envelops cells. Mucus and glycocalyx barriers derive their function, both passive and active, from mucin …
- 230000003612 virological effect 0 title description 40
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wong et al. | The SARS-coronavirus infection cycle: a survey of viral membrane proteins, their functional interactions and pathogenesis | |
| Ahmed et al. | Human antimicrobial peptides as therapeutics for viral infections | |
| Kim | SARS-CoV-2 evolutionary adaptation toward host entry and recognition of receptor O-Acetyl sialylation in virus–host interaction | |
| Soria-Martinez et al. | Prophylactic antiviral activity of sulfated glycomimetic oligomers and polymers | |
| Koehler et al. | Initial step of virus entry: virion binding to cell-surface glycans | |
| Hao et al. | Binding of the SARS-CoV-2 spike protein to glycans | |
| Hendricks et al. | Sialylneolacto-N-tetraose c (LSTc)-bearing liposomal decoys capture influenza A virus | |
| Dey et al. | Multivalent flexible nanogels exhibit broad-spectrum antiviral activity by blocking virus entry | |
| Shajahan et al. | Glycosylation of SARS-CoV-2: structural and functional insights | |
| Helander et al. | The viral σ1 protein and glycoconjugates containing α2-3-linked sialic acid are involved in type 1 reovirus adherence to M cell apical surfaces | |
| Harvey et al. | Gonococcal lipooligosaccharide is a ligand for the asialoglycoprotein receptor on human sperm | |
| Arend | Why blood group A individuals are at risk whereas blood group O individuals are protected from SARS-CoV-2 (COVID-19) infection: A hypothesis regarding how the virus invades the human body via ABO (H) blood group-determining carbohydrates | |
| Nassar et al. | A review of human coronaviruses’ receptors: the host-cell targets for the crown bearing viruses | |
| Bomsel et al. | Entry of viruses through the epithelial barrier: pathogenic trickery | |
| Wang et al. | Spike glycoprotein-mediated entry of SARS coronaviruses | |
| Byrnes et al. | Binding of Sindbis virus to cell surface heparan sulfate | |
| François et al. | Potential of carbohydrate‐binding agents as therapeutics against enveloped viruses | |
| Wielgat et al. | Coronaviruses: is sialic acid a gate to the eye of cytokine storm? From the entry to the effects | |
| Wardzala et al. | Mucins inhibit coronavirus infection in a glycan-dependent manner | |
| TWI333959B (en) | Methods and reagents for the analysis and purification of polysaccharides | |
| Kim et al. | Multivalent glycans for biological and biomedical applications | |
| JP4959110B2 (en) | Anti-pathogen treatment | |
| Li et al. | The invasion of tobacco mosaic virus RNA induces endoplasmic reticulum stress-related autophagy in HeLa cells | |
| Suzuki et al. | Human host defense cathelicidin peptide LL-37 enhances the lipopolysaccharide uptake by liver sinusoidal endothelial cells without cell activation | |
| Aloor et al. | Glycosylation in SARS-CoV-2 variants: A path to infection and recovery |